Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Merck
Medtronic
Harvard Business School
Colorcon

Last Updated: October 1, 2022

OLINVYK Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Olinvyk patents expire, and what generic alternatives are available?

Olinvyk is a drug marketed by Trevena and is included in one NDA. There are four patents protecting this drug.

This drug has forty-nine patent family members in twenty-three countries.

The generic ingredient in OLINVYK is oliceridine. Additional details are available on the oliceridine profile page.

DrugPatentWatch® Generic Entry Outlook for Olinvyk

Olinvyk will be eligible for patent challenges on October 30, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 23, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for OLINVYK
International Patents:49
US Patents:4
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 26
Patent Applications: 69
What excipients (inactive ingredients) are in OLINVYK?OLINVYK excipients list
DailyMed Link:OLINVYK at DailyMed
Drug patent expirations by year for OLINVYK
DrugPatentWatch® Estimated Generic Entry Opportunity Date for OLINVYK
Generic Entry Date for OLINVYK*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for OLINVYK

US Patents and Regulatory Information for OLINVYK

OLINVYK is protected by four US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of OLINVYK is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting OLINVYK

Opioid receptor ligands and methods of using and making same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION

Opioid receptor ligands and methods of using and making same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION

Opioid receptor ligands and methods of using and making same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION

Opioid receptor ligands and methods of using and making same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION

FDA Regulatory Exclusivity protecting OLINVYK

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-001 Oct 30, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-002 Oct 30, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-001 Oct 30, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-003 Oct 30, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-002 Oct 30, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-003 Oct 30, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for OLINVYK

When does loss-of-exclusivity occur for OLINVYK?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 12230761
Estimated Expiration: See Plans and Pricing

Patent: 17200745
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2013024136
Estimated Expiration: See Plans and Pricing

Canada

Patent: 30742
Estimated Expiration: See Plans and Pricing

China

Patent: 3702561
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0171021
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 19057
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 88403
Estimated Expiration: See Plans and Pricing

Patent: 90415
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 5456
Estimated Expiration: See Plans and Pricing

Patent: 1391332
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 88403
Estimated Expiration: See Plans and Pricing

Patent: 90415
Estimated Expiration: See Plans and Pricing

Patent: 72076
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 50984
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 32948
Estimated Expiration: See Plans and Pricing

Patent: 54055
Estimated Expiration: See Plans and Pricing

Israel

Patent: 8506
Estimated Expiration: See Plans and Pricing

Patent: 3318
Estimated Expiration: See Plans and Pricing

Patent: 2165
Estimated Expiration: See Plans and Pricing

Patent: 4407
Estimated Expiration: See Plans and Pricing

Japan

Patent: 12169
Estimated Expiration: See Plans and Pricing

Patent: 43949
Estimated Expiration: See Plans and Pricing

Patent: 49341
Estimated Expiration: See Plans and Pricing

Patent: 23683
Estimated Expiration: See Plans and Pricing

Patent: 14508811
Estimated Expiration: See Plans and Pricing

Patent: 16155843
Estimated Expiration: See Plans and Pricing

Patent: 18048193
Estimated Expiration: See Plans and Pricing

Patent: 20073570
Estimated Expiration: See Plans and Pricing

Patent: 21176885
Estimated Expiration: See Plans and Pricing

Lithuania

Patent: 88403
Estimated Expiration: See Plans and Pricing

Montenegro

Patent: 754
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 5993
Estimated Expiration: See Plans and Pricing

Patent: 3143
Estimated Expiration: See Plans and Pricing

Poland

Patent: 88403
Estimated Expiration: See Plans and Pricing

Patent: 90415
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 88403
Estimated Expiration: See Plans and Pricing

Patent: 90415
Estimated Expiration: See Plans and Pricing

Serbia

Patent: 111
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 88403
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1991326
Estimated Expiration: See Plans and Pricing

Patent: 1991327
Estimated Expiration: See Plans and Pricing

Patent: 2129247
Estimated Expiration: See Plans and Pricing

Patent: 140047599
Estimated Expiration: See Plans and Pricing

Patent: 180100453
Estimated Expiration: See Plans and Pricing

Patent: 190072665
Estimated Expiration: See Plans and Pricing

Spain

Patent: 32009
Estimated Expiration: See Plans and Pricing

Patent: 57549
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OLINVYK around the world.

Country Patent Number Title Estimated Expiration
Japan 2014508811 See Plans and Pricing
China 103702561 Opioid receptor ligands and methods of using and making same See Plans and Pricing
Denmark 3290415 See Plans and Pricing
New Zealand 615993 Opioid receptor ligands and methods of using and making same See Plans and Pricing
Eurasian Patent Organization 025456 ЛИГАНДЫ ОПИОИДНЫХ РЕЦЕПТОРОВ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ И ПОЛУЧЕНИЯ (OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME) See Plans and Pricing
Israel 272165 ליגנדים של קולטן אופיואיד ושיטות לשימוש בהם ולהכנתם (Opioid receptor ligands and methods of using and making same) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Johnson and Johnson
McKinsey
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.